The heterogeneity of CAFs and immune cell populations in the tumor microenvironment of pancreatic adenocarcinoma

Abstract

Over the past decade, researchers have identified and characterized the diverse cell populations within the tumor microenvironment of pancreatic cancer. The interplay between these cells in the TME either promotes or inhibits the malignant behavior of pancreatic cancer cells. Cancer-associated fibroblasts, previously thought to be one main subset, can now be broadly subclassified into three main types: inflammatory, myofibroblastic, and antigen-presenting, with the former and the latter two exerting pro-tumoral and anti-tumoral functions, respectively. Myeloid cells include myeloid-derived suppressor cells and tumor-associated macrophages. Myeloid-derived suppressor cells can be further divided into polymorphonuclear and monocytic and exhibit pro-tumoral activities. Tumor-associated macrophages exhibit M1 (anti-tumoral) or M2 (pro-tumoral) phenotypes, which are present in a dynamic fashion between the two phenotypes. Other constituents of the immune make-up of the tumor microenvironment include T and B cells and less described subsets which include natural killer cells, γδ T cells, and group 2 innate lymphoid cells. This review provides an overview of the studies that lead to the discovery of those cellular populations and highlights the recent efforts to utilize them as therapeutic targets in pancreatic cancer.

Keywords

Tumor microenvironment / pancreatic cancer / cancer-associated fibroblast / myeloid cells / T cells

References

[1] Rahib L,Aizenberg R,Fleshman JM.Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.Cancer Res2014;74:2913-21

[2] Siegel RL,Fuchs HE.Cancer statistics, 2022.CA Cancer J Clin2022;72:7-33

[3] Al-Share B,Diab M.Pancreatic adenocarcinoma: molecular drivers and the role of targeted therapy.Cancer Metastasis Rev2021;40:355-71

[4] Conroy T,Ychou M.FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.N Engl J Med2011;364:1817-25

[5] Singh RR.New treatment strategies for metastatic pancreatic ductal adenocarcinoma.Drugs2020;80:647-69 PMCID:PMC7466866

[6] Väyrynen SA,Yuan C.Composition, spatial characteristics, and prognostic significance of myeloid cell infiltration in pancreatic cancer.Clin Cancer Res2021;27:1069-81 PMCID:PMC8345232

[7] Park W,O’Reilly EM.Pancreatic cancer: a review.JAMA2021;326:851-62

[8] Vaish U,Are AC.Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma: an update on heterogeneity and therapeutic targeting.Int J Mol Sci2021;22:13408 PMCID:PMC8706283

[9] Gopurappilly R,Bhonde R.Pancreatic tissue resident mesenchymal stromal cell (MSC)-like cells as a source of in vitro islet neogenesis.J Cell Biochem2013;114:2240-7

[10] Quante M,Tomita H.Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth.Cancer Cell2011;19:257-72 PMCID:PMC3060401

[11] Mathew E,Del Vecchio A.Mesenchymal stem cells promote pancreatic tumor growth by inducing alternative polarization of macrophages.Neoplasia2016;18:142-51 PMCID:PMC4796803

[12] Zeisberg EM,Xie L,Kalluri R.Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts.Cancer Res2007;67:10123-8

[13] Iwano M,Danoff TM,Okada H.Evidence that fibroblasts derive from epithelium during tissue fibrosis.J Clin Invest2002;110:341-50 PMCID:PMC151091

[14] Özdemir BC,Carstens JL.Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival.Cancer Cell2014;25:719-34 PMCID:PMC4180632

[15] Chen Y,Yang S.Type I collagen deletion in αSMA⁺ myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer.Cancer Cell2021;39:548-565.e6 PMCID:PMC8423173

[16] Bhattacharjee S,Ravichandra A.Tumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts.J Clin Invest2021;131:146987 PMCID:PMC8159701

[17] Lee JJ,Wang H.Stromal response to Hedgehog signaling restrains pancreatic cancer progression.Proc Natl Acad Sci USA2014;111:E3091-100 PMCID:PMC4121834

[18] Walter K,Hong SM.Overexpression of smoothened activates the sonic hedgehog signaling pathway in pancreatic cancer-associated fibroblasts.Clin Cancer Res2010;16:1781-9 PMCID:PMC2846609

[19] Catenacci DV,Karrison T.Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer.J Clin Oncol2015;33:4284-92 PMCID:PMC4678179

[20] Elyada E,Laise P.Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts.Cancer Discov2019;9:1102-23 PMCID:PMC6727976

[21] Baron M,Wolock SL.A single-cell transcriptomic map of the human and mouse pancreas reveals inter- and intra-cell population structure.Cell Syst2016;3:346-360.e4 PMCID:PMC5228327

[22] Bernard V,Huang J.Single-cell transcriptomics of pancreatic cancer precursors demonstrates epithelial and microenvironmental heterogeneity as an early event in neoplastic progression.Clin Cancer Res2019;25:2194-205 PMCID:PMC6445737

[23] Dominguez CX,Keerthivasan S.Single-cell RNA sequencing reveals stromal evolution into LRRC15⁺ myofibroblasts as a determinant of patient response to cancer immunotherapy.Cancer Discov2020;10:232-53

[24] Hosein AN,Wang Z.Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution.JCI Insight2019;5:129212 PMCID:PMC6777805

[25] Öhlund D,Biffi G.Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer.J Exp Med2017;214:579-96 PMCID:PMC5339682

[26] Biffi G,Spielman B.IL1-induced JAK/STAT signaling is antagonized by TGFβ to shape CAF heterogeneity in pancreatic ductal adenocarcinoma.Cancer Discov2019;9:282-301 PMCID:PMC6368881

[27] Van Cutsem E,Sigal D.Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma.J Clin Oncol2020;38:3185-94 PMCID:PMC7499614

[28] Ramanathan RK,Philip PA.Phase IB/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313.J Clin Oncol2019;37:1062-9 PMCID:PMC6494359

[29] Kemp SB,Crawford HC.Myeloid cell mediated immune suppression in pancreatic cancer.Cell Mol Gastroenterol Hepatol2021;12:1531-42 PMCID:PMC8529393

[30] Sharma V,Jacob J.Myeloid-derived suppressor cells: bridging the gap between inflammation and pancreatic adenocarcinoma.Scand J Immunol2021;93:e13021

[31] Bronte V,Chen SH.Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards.Nat Commun2016;7:12150 PMCID:PMC4935811

[32] Vanhaver C,Bruger AM.MDSC in mice and men: mechanisms of immunosuppression in cancer.J Clin Med2021;10:2872 PMCID:PMC8268873

[33] Trovato R,Sartori S.Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3.J Immunother Cancer2019;7:255 PMCID:PMC6751612

[34] Ugel S,Mandruzzato S.Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages.J Clin Invest2015;125:3365-76 PMCID:PMC4588310

[35] Huang B,Li Q.Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host.Cancer Res2006;66:1123-31

[36] Zhang Y,Mathew E.Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer.Gut2017;66:124-36 PMCID:PMC5256390

[37] Chao T,Vonderheide RH.CXCR2-dependent accumulation of tumor-associated neutrophils regulates T-cell immunity in pancreatic ductal adenocarcinoma.Cancer Immunol Res2016;4:968-82 PMCID:PMC5110270

[38] Bayne LJ,Jhala N.Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer.Cancer Cell2012;21:822-35 PMCID:PMC3575028

[39] Pylayeva-Gupta Y,Hajdu CH,Bar-Sagi D.Oncogenic kras-induced GM-CSF production promotes the development of pancreatic neoplasia.Cancer Cell2012;21:836-47 PMCID:PMC3721510

[40] Stromnes IM,Izeradjene K.Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity.Gut2014;63:1769-81 PMCID:PMC4340484

[41] Steele CW,Leach JDG.CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma.Cancer Cell2016;29:832-45 PMCID:PMC4912354

[42] Yang S,Liao Q.Tumor-associated macrophages in pancreatic ductal adenocarcinoma: origin, polarization, function, and reprogramming.Front Cell Dev Biol2020;8:607209 PMCID:PMC7829544

[43] Sanford DE,Panni RZ.Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis.Clin Cancer Res2013;19:3404-15 PMCID:PMC3700620

[44] Zhu Y,Sojka DK.Tissue-resident macrophages in pancreatic ductal adenocarcinoma originate from embryonic hematopoiesis and promote tumor progression.Immunity2017;47:323-338.e6

[45] Clark CE,Mick R,Tuveson DA.Dynamics of the immune reaction to pancreatic cancer from inception to invasion.Cancer Res2007;67:9518-27

[46] Ziske C,Eliu AS.Increase of in vivo antitumoral activity by CD40L (CD154) gene transfer into pancreatic tumor cell-dendritic cell hybrids.Pancreas2009;38:758-65

[47] Liu Q,Niu Z.Atorvastatin (Lipitor) attenuates the effects of aspirin on pancreatic cancerogenesis and the chemotherapeutic efficacy of gemcitabine on pancreatic cancer by promoting M2 polarized tumor associated macrophages.J Exp Clin Cancer Res2016;35:33 PMCID:PMC4754966

[48] Poh AR.Tumor-associated macrophages in pancreatic ductal adenocarcinoma: therapeutic opportunities and clinical challenges.Cancers2021;13:2860 PMCID:PMC8226457

[49] Candido JB,Bailey P.CSF1R⁺ macrophages sustain pancreatic tumor growth through T Cell suppression and maintenance of key gene programs that define the squamous subtype.Cell Rep2018;23:1448-60 PMCID:PMC5946718

[50] Zhu Y,Meyer MA.CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.Cancer Res2014;74:5057-69 PMCID:PMC4182950

[51] Wang-gillam A,Bendell JC.A randomized phase II study of cabiralizumab (cabira) + nivolumab (nivo) ± chemotherapy (chemo) in advanced pancreatic ductal adenocarcinoma (PDAC).JCO2019;37:TPS465

[52] Nywening TM,Sanford DE.Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.Lancet Oncol2016;17:651-62 PMCID:PMC5407285

[53] Noel M,Wolpin BM.Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma.Invest New Drugs2020;38:800-11 PMCID:PMC7211198

[54] Beatty GL,Fishman MP.CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.Science2011;331:1612-6 PMCID:PMC3406187

[55] Beatty GL,Evans RA.Exclusion of T cells from pancreatic carcinomas in mice is regulated by Ly6C(low) F4/80(+) extratumoral macrophages.Gastroenterology2015;149:201-10 PMCID:PMC4478138

[56] Winograd R,Evans RA.Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma.Cancer Immunol Res2015;3:399-411 PMCID:PMC4390506

[57] O’hara MH,Varadhachary G.CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.Lancet Oncol2021;22:118-31

[58] Lee JW,Porrett PM.Hepatocytes direct the formation of a pro-metastatic niche in the liver.Nature2019;567:249-52 PMCID:PMC6430113

[59] Nielsen SR,Linford A.Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis.Nat Cell Biol2016;18:549-60

[60] Lohneis P,Bischoff S.Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma.Eur J Cancer2017;83:290-301

[61] Steele NG,Kemp SB.Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer.Nat Cancer2020;1:1097-112 PMCID:PMC8294470

[62] Topcu KSB,Menevse E,Duran T.Investigation of the effects of the toll-like receptor 4 pathway on immune checkpoint vista in pancreatic cancer.Invest New Drugs2022;40:519-28

[63] Hou Z,Fei Q.Prognostic significance and therapeutic potential of the immune checkpoint VISTA in pancreatic cancer.J Cancer Res Clin Oncol2021;147:517-31 PMCID:PMC7817580

[64] Frey N,Egli D.Loss of Rnf31 and Vps4b sensitizes pancreatic cancer to T cell-mediated killing.Nat Commun2022;13:1804 PMCID:PMC8980030

[65] Tian C,Clauser KR.Suppression of pancreatic ductal adenocarcinoma growth and metastasis by fibrillar collagens produced selectively by tumor cells.Nat Commun2021;12:2328 PMCID:PMC8058088

[66] Sahai E,Cukierman E.A framework for advancing our understanding of cancer-associated fibroblasts.Nat Rev Cancer2020;20:174-86 PMCID:PMC7046529

[67] Akce M,Diab M.Phase Ib/II trial of siltuximab and spartalizumab in patients in metastatic pancreatic cancer.JCO2022;40:TPS626-TPS626

[68] Bockorny B,Macarulla T.BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial.Nat Med2020;26:878-85

[69] Seo YD,Sullivan KM.Mobilization of CD8⁺ T cells via CXCR4 blockade facilitates PD-1 checkpoint therapy in human pancreatic cancer.Clin Cancer Res2019;25:3934-45 PMCID:PMC6606359

[70] Feig C,Kraman M.Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.Proc Natl Acad Sci USA2013;110:20212-7 PMCID:PMC3864274

[71] Goulart MR,Fincham REA,Kocher HM.T cells in pancreatic cancer stroma.World J Gastroenterol2021;27:7956-68 PMCID:PMC8678814

[72] Diana A,D’Costa Z.Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.Oncotarget2016;7:40992-1004 PMCID:PMC5173037

[73] Tang Y,Guo S.An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma.PLoS One2014;9:e91551 PMCID:PMC3956642

[74] Zhang Y,Steele NG.Regulatory T-cell depletion alters the tumor microenvironment and accelerates pancreatic carcinogenesis.Cancer Discov2020;10:422-39 PMCID:PMC7224338

[75] McAllister F,Alsina J.Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia.Cancer Cell2014;25:621-37 PMCID:PMC4072043

[76] Zhang Y,Riquelme E.Immune cell production of interleukin 17 Induces stem cell features of pancreatic intraepithelial neoplasia cells.Gastroenterology2018;155:210-223.e3 PMCID:PMC6035075

[77] Barilla RM,Caso RC.Specialized dendritic cells induce tumor-promoting IL-10⁺IL-17⁺ FoxP3^neg regulatory CD4⁺ T cells in pancreatic carcinoma.Nat Commun2019;10:1424 PMCID:PMC6441038

[78] Pylayeva-Gupta Y,Handler JS.IL35-producing B cells promote the development of pancreatic neoplasia.Cancer Discov2016;6:247-55 PMCID:PMC5709038

[79] Roghanian A,Kleyman M.B Cells promote pancreatic tumorigenesis.Cancer Discov2016;6:230-2

[80] Castino GF,Capretti G.Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma.Oncoimmunology2016;5:e1085147 PMCID:PMC4839336

[81] Minici C,Lanzillotta M.B lymphocytes contribute to stromal reaction in pancreatic ductal adenocarcinoma.Oncoimmunology2020;9:1794359 PMCID:PMC7458626

[82] Tong DN,Sun JH.Characterization of B cell-mediated PD-1/PD-L1 interaction in pancreatic cancer patients.Clin Exp Pharmacol Physiol2020;47:1342-9

[83] Khan AR,Floudas A,Weaver CT.PD-L1hi B cells are critical regulators of humoral immunity.Nat Commun2015;6:5997

[84] Gunderson AJ,Tsujikawa T.Bruton tyrosine kinase-dependent immune cell cross-talk drives pancreas cancer.Cancer Discov2016;6:270-85 PMCID:PMC4783268

[85] Tempero M,Tabernero J.Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study.Ann Oncol2021;32:600-8

[86] Philip PA.Targeting B cells in pancreatic adenocarcinoma: does RESOLVE resolve the question?.Ann Oncol2021;32:582-3

[87] Byrne KT.CD40 stimulation obviates innate sensors and drives T cell immunity in cancer.Cell Rep2016;15:2719-32 PMCID:PMC4917417

[88] Ma HS,Torres ER.A CD40 agonist and PD-1 antagonist antibody reprogram the microenvironment of nonimmunogenic tumors to allow T-cell-mediated anticancer activity.Cancer Immunol Res2019;7:428-42 PMCID:PMC6397686

[89] Byrne KT,Mick R.Neoadjuvant selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer.Clin Cancer Res2021;27:4574-86 PMCID:PMC8667686

[90] Yang J.Dendritic cells in pancreatic cancer immunotherapy: vaccines and combination immunotherapies.Pathol Res Pract2019;215:152691

[91] Yang J,Eresen A,Wang J.Dendritic cells in pancreatic cancer immunotherapy: vaccines and combination immunotherapies.Pathol Res Pract2019;215:152691

[92] Hirooka S.The role of circulating dendritic cells in patients with unresectable pancreatic cancer.Anticancer Res2011;31:3827-34

[93] Yamamoto T,Satoi S.Circulating myeloid dendritic cells as prognostic factors in patients with pancreatic cancer who have undergone surgical resection.J Surg Res2012;173:299-308

[94] Fukunaga A,Cho Y.CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma.Pancreas2004;28:e26-31

[95] Dallal RM,Lee K,Son YI.Paucity of dendritic cells in pancreatic cancer.Surgery2002;131:135-8

[96] Baylor college of medicine, N. Th-1 Dendritic cell immunotherapy plus standard chemotherapy for pancreatic adenocarcinoma (DECIST). Available from: https://clinicaltrials.gov/ct2/show/NCT04157127 [Last accessed on 27 September 2022].

[97] Katsuda M,Ojima T.A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemotherapy.Trials2019;20:242 PMCID:PMC6486956

[98] Nagai K,Harada H,Sugiyama H.Dendritic cell-based immunotherapy pulsed with wilms tumor 1 peptide and mucin 1 as an adjuvant therapy for pancreatic ductal adenocarcinoma after curative resection: a phase I/IIa clinical trial.Anticancer Res2020;40:5765-76

[99] Hoshikawa M,Matsushita H.NK cell and IFN signatures are positive prognostic biomarkers for resectable pancreatic cancer.Biochem Biophys Res Commun2018;495:2058-65

[100] Lim SA,Jeon S.Defective localization with impaired tumor cytotoxicity contributes to the immune escape of NK cells in pancreatic cancer patients.Front Immunol2019;10:496 PMCID:PMC6465515

[101] Dickson I.Pancreatic cancer: γδ T cells support PDAC.Nat Rev Gastroenterol Hepatol2016;13:560

[102] Seifert AM,Heiduk M.Gamma-delta T cells stimulate IL-6 production by pancreatic stellate cells in pancreatic ductal adenocarcinoma.J Cancer Res Clin Oncol2020;146:3233-40 PMCID:PMC7679341

[103] Chiossone L,Vienne M.Natural killer cells and other innate lymphoid cells in cancer.Nat Rev Immunol2018;18:671-88

[104] Moral JA,Rojas LA.ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity.Nature2020;579:130-5 PMCID:PMC7060130